Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of High-Dose GMA301 in Healthy Volunteers
NCT04505137Phase 1Completed
- Sponsor
- Gmax Biopharm
- Start
- Sep 2020
- Primary completion
- Mar 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GMA301 in pulmonary arterial hypertension (PAH) (2 cohorts), sponsored by Gmax Biopharm. Primary endpoint: Safety and Tolerability (Adverse Events) at Day 70. Started Sep 2020; status: completed.
02
Drugs
GMA301
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04505137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04505137.